News

ALK spotlights the impact of respiratory allergies on children at EAACI Congress

Four leading experts in respiratory allergy spotlight the impact of respiratory allergy in children, in an ALK-sponsored symposium at the…

2 years ago

VIVO Cannabis Announces Results of 2022 AGM and Election of New Directors

Toronto, Ontario--(Newsfile Corp. - July 2, 2022) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) ("VIVO" or the "Company"), a…

2 years ago

Innovation Vista Named Most Promising Digital Transformation Firm

Los Angeles, California--(Newsfile Corp. - July 1, 2022) - CIO Review announces Innovation Vista as Most Promising Emerging Digital Transformation…

2 years ago

ClexBio Announces New Appointments to Board of Directors

OSLO, Norway & BOSTON--(BUSINESS WIRE)--ClexBio, an early-stage biotech company developing next-generation tissue engineered grafts for transplant, is announcing the appointment…

2 years ago

ProAssurance Second Quarter 2022 Results Release and Teleconference

BIRMINGHAM, Ala.--(BUSINESS WIRE)--ProAssurance Corporation (NYSE:PRA) will report results for the quarter ended June 30, 2022 after the close of normal…

2 years ago

Philips Signs Health Care Sector Pledge to Reduce Emissions as part of Department of Health and Human Services, White House Initiative

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the company has joined…

2 years ago

Vaxart Provides an Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022 to Vote by July 5, 2022, at 11:59 p.m. ET

Key Proposal #2 has received significant support, but additional votes are needed for approval Leading Independent Proxy Advisory Firms, ISS…

2 years ago

Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors

BOSTON and LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a…

2 years ago

Biomea Fusion Selected for Two Oral Presentations at the European Association for the Study of Diabetes Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting, Acute Treatment for Type 2 Diabetes

Biomea to present two oral abstracts across multiple animal models highlighting the ability of BMF-219, a covalent menin inhibitor, to…

2 years ago

GeneType Risk Assessment Test onboarding in 16 clinics

MELBOURNE, Australia, July 01, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader…

2 years ago